PPHM and Tarvacin discussion

[Preciouslife1]

I am trying to find other shareholders in PPHM who want to discuss PPHM and Tarvacins/Bavituximab's prospects.



***DISCLAIMER: This message board is not affiliated with Peregrine Pharmaceuticals. No endorsement by Peregrine Pharmaceuticals. or any other organization is implied.

[Leonid]

We strongly encourage any discussion here, but can you please be more specific?

What are the issues you are talking about?

[Andreea]

Originally Posted by Preciouslife1

I am trying to find other shareholders in PPHM who want to discuss PPHM and Tarvacins prospects.

As far as I know Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and viral diseases. The company is pursuing three separate medical trials in cancer and anti-viral indications with its lead product candidates Tarvacin(TM) and Cotara(R).

Tarvacin Anti-Cancer is a monoclonal antibody that binds specifically to phospholipids, a basic component of the cell structure that is exposed only on the surface of tumor blood vessel cells and is not present on normal cells.

I would be more than gald to learn more about the outcome of these clinical trials and how exactly does Tarvacin works. I have a slight idea about how it works: it seems to trigger and allert the immune system to attack the tumor and its blood supply while minimizing effects on non-targeted healthy cells.

Looking forward to discuss this topic!

[Preciouslife1]

Hello and thanx for the response. I have been a shareholder in PPHM since '99 in the Techniclone days. What PPHM has in Tarvacin could be the most amazing drug discovery in a long time. I post on Raging Bull PPHM board under Preciouslife1 and you can go there and read my posts and others there about Tarvacin and Cotara. In short, Tarvacin has shown by Dr. Philip Thorpe of UTSW, to eradicate all enveloped viruses including Influenza, Lassa, Marburg, Ebola etc. without doing damage to the system. Go to Google and do Tarvacin search or PPHM home page and you will see what I mean. They are in a HepC trial here in Sarasota, just got into MD Anderson for cancer, Duke Medical Center, Tulane Medical Center , 2 trials in Arizona etc. There is a plethora of info out especially from the recent shareholders meeting. The drawbacks with PPHM is that it a small biotech with limited financing, a poor history of leadeship and missed targets and bad financing deals. Tarvacin can reverse alot of the past mistakes, especially with Cotara for brain cancer which showed great results and efficacy. The 160+ million OS shares is also a problem and 50 million more are authorized. Anyway, I watched Viropharma go from $1.67 to over $24 in 3 months so this could happen here with good human data from the trials. Here are some links to read when you have time t do due diligence or just learn about this amazing new drugs potential.

http://www.rxpgnews.com/world/epidem...cle_2702.shtml

http://biz.yahoo.com/prnews/051021/laf022.html?.v=26

http://ir.peregrineinc.com/phoenix.z...&p=irol-irhome

http://www.medicalnewstoday.com/medi...p?newsid=23162

http://www.medicalnewstoday.com/medi...p?newsid=29355

http://www.rxpgnews.com/cancer/article_1579.shtml

http://www.clinicaltrials.gov/ct/show/NCT00129337


http://www.news-medical.net/?id=10060

Why Iosw This Stoch Being Held Down ?

Why Isn"t There Better P.r. From This Company ?

[Preciouslife1]

due to Large amount of OS and the dilutive fianacings from the past. However, the Tatvacin trials have been going on and Positive Human data is what will drive the shares higher imo. Getting into MD Anderson, Duke, Tulane, Godofsky centers shows the great potential for Tarvacin as an adjuvant and stand alone therapy.
If you read up on what results is has had so far it is amazing. There is a plethora of info on Google about Tarvacin and Cotara their drug now in trials again for Glioblastoma Multiforme. You know how the game is played on the street where the big $$$ money boys control the market makers and offhore hedge funds are able to "manipulate" share prices to their whim sans positive news events.
At $1, it is very cheap considering the vast potential for Tarvacin in anti viral and anti cancer treatments. Take care..PL1

Thank you for the responce.

Any one care to guess the value in short term ( sixty days ) long term ( one year ) ?

I have heard $3-5 soon and could go to $25 plus !

[Preciouslife1]

Peregrine Pharmaceuticals Names Leading Viral Experts to Its Scientific Resource Board
Wednesday November 16, 7:00 am ET
- Addition of Thought Leaders Alfred M. Prince, M.D. and Peter Barry, Ph.D. Strengthens Peregrine's Programs in Hepatitis C and Cytomegalovirus -


TUSTIN, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, announced today the appointment of Alfred M. Prince, M.D., a hepatitis expert, and Peter Barry, Ph.D., a leader in the study of cytomegalovirus (CMV), to its Scientific Resource Board. Their expertise in specific viral infections will support Peregrine's development of Tarvacin(TM) Anti-Viral, an investigational monoclonal antibody therapy with unique anti-viral properties. Tarvacin Anti-Viral is in a Phase I clinical trial for the treatment of chronic hepatitis C infection (HCV) and is being studied preclinically for use in the treatment of CMV, HIV and influenza infections.
ADVERTISEMENT


Dr. Prince is a world-renowned virologist with a focus on hepatitis and he was the first to report the existence of the virus now termed hepatitis C. Dr. Prince is founding chairman of the Hepatitis Research Foundation and currently serves as head of the Laboratory of Virology for The New York Blood Center.

Dr. Barry's research addresses how CMV, a clinically serious infection in infants and immuno-compromised adults, affects the host organism during the course of infection, as well as mechanisms of CMV persistence and pathogenesis for this ubiquitous member of the herpes virus family. His laboratory was instrumental in developing the only existing non-human primate model for human CMV. Dr. Barry is currently an associate professor in the Department of Pathology and Laboratory Medicine at the University of California, Davis. He is also a core faculty member of the Center for Comparative Medicine and a staff scientist at the California National Primate Research Center. Additional biographical material on both researchers follows below.

"The addition of Dr. Prince's and Dr. Barry's expertise will be instrumental as we continue our clinical study of Tarvacin Anti-Viral in patients with chronic hepatitis C and evaluate future clinical studies in the treatment of CMV," said Steven King, president and CEO of Peregrine Pharmaceuticals. "They join our Scientific Resource Board at an exciting time for our anti-viral program. Both HCV and CMV currently lack adequate therapies and we are optimistic that Tarvacin Anti-Viral may have promise as an effective new therapeutic approach."

Peregrine is conducting a Phase I clinical trial to evaluate Tarvacin Anti-Viral in the treatment of chronic hepatitis C infection, which is an important source of disability and death among the estimated 3.9 million infected Americans and is also the major cause of liver transplantation in the U.S. Earlier this year, Peregrine presented promising preclinical data supporting the potential of Tarvacin Anti-Viral for the treatment of CMV, which can cause serious health problems for individuals with a compromised immune system.

Tarvacin is an antibody that attaches to phospholipids, specific cellular components that are exposed on the surface of virally infected cells and on enveloped virus particles. Peregrine has reported that Tarvacin binds to members of six different families of enveloped viruses. Tarvacin also binds to phospholipids exposed on solid tumor blood vessels and is currently in a Phase I clinical trial for patients with advanced refractory solid tumors.

As members of the Peregrine SRB, Drs. Barry and Prince will be joining Drs. Preston Marx and Stephen Smith, who provide expertise in the treatment of HIV and other viral indications and Drs. Philip Thorpe and Melina Soares who developed the Tarvacin Anti-Viral platform.

Peter Barry, Ph.D.

Dr. Barry has extensive experience in many aspects of virology, cell biology, immunology and molecular biology with a main emphasis on the elucidation of the mechanisms of rhesus CMV persistence and pathogenesis as a non-human primate model of human CMV. Development of the macaque model is important because human CMV is strictly species-specific and macaques share strong immunologic, physiologic, developmental and evolutionary relationships with humans. Dr. Barry's research goals have addressed two broad areas. The first focuses on the mechanisms enabling the virus to establish lifelong persistence in an immunocompetent host despite the development of vigorous antiviral immune responses. In particular, his research focuses on those viral proteins that modulate host immune response. The second research focus is directed towards a better understanding of the mechanisms of CMV pathogenesis in rhesus monkeys during fetal infection and simian AIDS, two highly relevant models of human CMV disease in humans. Knowledge from these two research interests is being applied by Dr. Barry's laboratory towards the development of novel anti-CMV vaccines and chemotherapeutic strategies to limit CMV infection and disease potential.

Alfred Prince, M.D.

Dr. Prince is a world-renowned virologist with expert focus on hepatitis. Currently, Dr. Prince is head of the Laboratory of Virology for The New York Blood Center, research professor of pathology at New York University School of Medicine, founding chairman of the Hepatitis Research Foundation and founding chairman of the International Consortium for Blood Safety. Dr. Prince was first to demonstrate the role of hepatitis B virus (HBV) in chronic liver disease; introduced the world's first blood screening for HBV at the New York Blood Center; was first to report the existence of the virus now termed HCV that causes post-transfusion hepatitis distinct from HBV; developed the first low-cost HBV vaccine; developed the first procedure for sterilization of blood to eliminate the risk of HBV, HCV and HIV transmission by blood products; developed an immunotherapy for chronic HBV infection in a chimpanzee model; founded the International Task Force for Hepatitis B Immunization which accelerated universal immunization against HBV worldwide; founded the International Consortium for Blood Safety and developed a multivalent vaccine candidate for HBV, HCV and HIV.

[Preciouslife1]

Adding these prominent and renowned scientists to PPHM's
thinktank is a major coup and wouldn't have happened without the AMAZING promise of Tarvacin. Add these world class minds to DR.Thorpe, and you have the foundation being built for actual PPHM CREDIBILTY to go along with the science. Now all they need is capital without having to slit their throat to get it.

Preston. A. Marx, Ph.D., a leading researcher in the cause and spread of HIV and other viral diseases and Stephen M. Smith, M.D., a prominent physician and researcher in the treatment of viral and infectious diseases.
and today these two added to

PPHM, a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, announced today the appointment of Alfred M. Prince, M.D., a hepatitis expert, and Peter Barry, Ph.D., a leader in the study of cytomegalovirus (CMV), to its Scientific Resource Board.
PPHM now in trials at MD Anderson, Duke Medical, Tulane Medical< Godofsky Hep C center, UTSW, and other sites which are all world renowned.

These are the kind of people that attract attention, respect, capital infusion, and help bring a potential multi blockbuster platform in antiviral and cancer to fruition. All IHO as always. PL1

[terrygd]

I don't know if this has been covered or not.
HHS Pandemic Influenza Plan

7: Antiviral Drug Distribution and Use


i) Contingency planning for Investigational New Drug (IND) use.

State and local health departments should be prepared to distribute unlicensed
antiviral drugs (if needed) under FDA's
Investigational New Drug (IND) provisions. IND provisions require strict
inventory control and recordkeeping, completion of a
signed consent form from each person who receives the medication, and mandatory
reporting of specified types of adverse
events. IND provisions also require approval of the protocol and consent form by
an Institutional Review Board (IRB). The FDA
regulations permit the use of a national or "central" IRB. A treatment IND is
one IND mechanism that FDA has available for
use and is especially suited for large scale use of investigational products.
http://www.access.gpo.gov/nara/cfr/waisidx_99/
21cfr_99.html
As an alternative to IND use of an unapproved antiviral drug, HHS may utilize
the drug product under Emergency Use
Authorization procedures as described in the FDA draft Guidance "Emergency Use
Authorization of Medical Products"
http://www.fda.gov/cber/gdlns/emeruse.pdf

[Preciouslife1]

This would be the first infections outside of Asia, and one of (if not THE) largest clusters yet.

more from Dr. Niman- (written earlier today, before the now breaking news of the confirmed testing)-

Suspect Bird Flu Cases In Turkey Grows to Fifteen

http://www.recombinomics.com/whats_new.html

Recombinomics Commentary
January 4, 2006

There are eight patients currently receiving treatment at Van University Hospital. All of them are from the town of Dogubeyazıt, Agri, which was subsequently quarantined due to fears of a bird flu outbreak in the region.

Five other children are expected to be taken to Van hospital also on suspicion of having contracted the bird flu virus.

The above report, combined with additional media reports suggest the number of patients hospitalized with bird flu symptoms in Turkey may have grown to 15.

The initial 4 cases were siblings. One, Muhammed Ali Kocygit (14), has died and his two sisters, Fatima (15) and Hulya (11) are in critical condition. Additional hospitalized patients include

Ali Hasan Kocygit (14)
Yusuf Tunc (5)
Semra Topcu (35)
Davut Polat(5)
Hatice Ozkan (15)
Aysegul Ozkan (9)
Yusuf Ozkan (3)

In addition to the 10 patients listed above, the latest report suggests an additional 5 children are being transported to the hospital.

The most detailed descriptions are for the four siblings who had a fever, bleeding from the gums, and pneumonia after eating a chicken that had died in a region close to H5 confirmed cases. Moreover, 3 of the 4 siblings are either dead or in critical condition, again raising the possibility of H5N1 infections, even though initial testing was negative.

More information on the additional cases would be useful. If those cases are as severe as the 4 siblings, then it seems that an easily transmissible agent is circulating in eastern Turkey, and H5N1 will remain a possibility until an alternative etiological agent is identified.

[Preciouslife1]

Yesterday Genbank put up several new sequences from Russian (Kurgan) birds- many species (including non-migratory...) All PB2's had E627K, - Which basically was the frightening warning in the massive Qinghai Lake die off this past year, sort of the 'ground zero' of all this mess...

(this little change in the PB2 gene allows the virus to feel more comfy and grow at lower temps- from 41C without this change- down to 34C with it- making the insides of our cool noses very hospitable for this H5N1). All human isolates of H1's ,H2's, & H3's have the lysine ("K") at position 627, and now so does H5N1... It seems to be doing everything right so far to really chow down on some human flesh sooner or later... And why not, the law of numbers (IMO) makes it seem pretty much inevitable it will get what it needs for more efficient human to human spread.

Hopefully it will be relatively mild, hopefully a long way off too.
One can hope.

j

the Vietnamese sparrow sequences are also out now.

PS-
The nasty little change to a more easy human to human spread, (S227N), can be had via recombination with H9N2, which also just happens to be endemic in birds in the middle east.

[Preciouslife1]

New Thorpe/Schroit ‘poster’ on 3G4/B2GPI recognized by UT-SW. It outlines the important role Beta2-Glycoprotein I (B2GPI) plays in the Anti-PS/3G4 binding process. Recall that Dr. Alan Schroit is an M.D.Anderson researcher, and on Peregrine’s SRB. He’s an expert on targeting phospholipids and the knowledge of cellular membrane expression of altered phospholipids in cancer cells. On 7-6-04, PPHM exclusively licensed this from Schroit/MDA:

“intellectual property related to anti-phosphatidylserine (Anti-PS) antibodies from The Univ. of Texas M. D. Anderson Cancer Center for use in mammalian therapeutics. The intellectual property, including U.S. Patent #6,300,308 (Methods And Compositions For Inducing Autoimmunity In The Treatment Of Cancers)…”.

My guess is that Schroit patent(s) for B2GPI (ex: 20030219406 ‘Beta-2-glycoprotein is an Inhibitor of Angiogenesis’ are already covered by the 7-2004 license. Also, I would imagine this poster, prepared with the help of Thorpe assistant Dr. Troy Luster, will form the basis of a presentation at the annual AACR meeting Apr. 1-5 2006 in Wash. DC, and perhaps at other venues.

3rd Annual Postdoctoral Symposium & Poster Session Winners - Fall 2005
Grand Prize Co-Winner: Dr. Troy Luster (Philip Thorpe, mentor)
http://www.utsouthwestern.edu/utsw/home/educ/gspostdocfellows/#3rd_Annual_Postdoctoral_Symposium_and...
((( Note: Dr. Luster is a member of Thorpe’s UTSW Lab. An example of his work is his presentation of a VEGF Thorpe/Rosenblum/Ran study (the VTA licensed by SUPG) at the 3-2005 AACR meeting: “VTA VEGF121/rGel inhibits the growth of human MDA-MB-231 breast tumors in the lungs of SCID mice” )))

New Thorpe/Schroit Poster, “Fall 2005”:

“Binding of a Monoclonal Antibody that Targets Anionic Phospholipids on Tumor Vasculature is Dependent upon Interaction with Plasma Protein Beta2-Glycoprotein I”
Troy A. Luster 1, Jin He 1, Xianming Huang 1, Alan J. Schroit 2, Philip E. Thorpe 1
1=Simmons Comprehensive Cancer Center, Hamon Center for Therapeutic Oncology Research, Dept. of Pharmacology, UTSW Medical Ctr., Dallas
2=Dept. of Cancer Biology, Univ. of Texas M. D. Anderson Cancer Ctr., Houston

[Preciouslife1]

Background: note 3G4 is Tarvacin.

Schroit is a member of Peregrine’s SRB, and in 7-2004, Peregrine exclusively licensed his “intellectual property related to anti-phosphatidylserine (Anti-PS) antibodies”, to round out Thorpe’s APT patent estate. The 7-6-04 PR stated, “The intellectual property, including U.S. Patent #6,300,308, ‘Methods And Compositions For Inducing Autoimmunity In The Treatment Of Cancers’…” In the “Fall of 2005”, Thorpe & Schroit co-authored a poster that outlines the important role Beta2-Glycoprotein I (B2GPI) plays in the Anti-PS/3G4 binding process.

Alan Schroit, Professor, UTMDACC, Cancer Biology
Univ. of Texas M.D. Anderson Cancer Center
http://gsbs.gs.uth.tmc.edu/tutorial/schroit.html

Alan Schroit: (9-2003)
Our research focuses on the chemistry, biology, and pathology of phosphatidylserine (PS) exposure in the outer leaflet of cells. The major goal of our research has been to understand the mechanism by which cells control the transbilayer distribution of phospholipids between the bilayer leaflet and the machinery responsible for the pathologic redistribution of phospholipids in different cell types. Theses studies are divided into several distinct projects.
In the first, we are investigating the role lipid peroxidation products play in the initiation, regulation and progression of apoptosis. Our studies have determined that defined intracellular redox pathways are critical to the generation of the apoptotic phenotype and in the regulation of lipid asymmetry in the apoptotic cell membrane. These studies suggest that cytochrome c is not only required for formation of the apoptosome, important in the activation of death-inducing caspases, but also functions as a regulator of the distribution of PS within the cell membrane. Our experiments are designed to test the hypothesis that the presence of both catalytic cytochrome c and hydrogen peroxide or lipid hydroperoxides as sources of oxidizing *************************alents, result in the formation of a highly active prooxidant form of cytochrome c that oxidizes membrane phospholipids in a self-propelled autocatalytic manner that culminates in PS exposure and cell death.

Another project focuses on identifying the molecular targets of beta-2-glycoprotein 1 (B2GP1), a 50-kDa plasma protein that mediates the binding of apoptotic and tumor cells to phagocytes. We are investigating the mechanism by which target cells are recognized by B2GP1 and the B2GP1-specific receptor on reticuloendothelial cells. Our results indicate that B2GP1 binds negatively charged lipids present on the surface of apoptotic and tumor cells that function as a primary target moiety. Recent studies suggest that B2GP1 is also a negative regulator of angiogenesis that can inhibit the growth of primary tumors and ********************stasis. Recent results raise the possibility that B2GP1 regulates tumor vascularity through a direct effect on a vascular endothelial growth factor (VEGF)-dependent mechanism. Ongoing experiments are designed to determine the mechanism by which this regulation occurs and develop B2GP1 as an antiangiogenic agent.

[Preciouslife1]

Please go back to page 14 as there is a lot of info down below that might get skipped over by the page shuffle here. Posts about H5N1 flu and Cotara, the brain cancer drug that PPHM has in trials and has been fast tracked by the FDA...PL1